2014
DOI: 10.4103/1319-2442.135209
|View full text |Cite
|
Sign up to set email alerts
|

Recipient characteristics and outcome of pediatric kidney transplantation at the king fahad specialist hospital-dammam

Abstract: The success of a pediatric kidney transplantation program can only be judged by reviewing its results. We aim to audit our short-term outcome of pediatric kidney transplantation at the King Fahad Specialist Hospital-Dammam. A retrospective chart review was performed to collect data about recipient demographics, etiology of end-stage kidney disease, type of dialysis, type of donor and outcome. Between September 2008 and April 2012, 35 pediatric kidney trans-plantations (<16 year) were performed of a total of 24… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 15 publications
0
1
0
Order By: Relevance
“…Jurim (1995) [79] USA R/C LT/RLT 0-10 Not described HAT 29% (LT) vs. 0% (RLT) Kamel (2006) [80] Ireland R/C KT 0-18 None GT 5% Kanmaz (2014) [13] Turkey R/C LT 0-18 ASA HAT 3.9%, PVT 6.8% Karatzas (1997) [81] USA R/C LT All Not described HAT 11.4% Khan (2014) [82] Saudi Arabia R/C KT 0- [86] Italy R/C LT, < 6 kg 0-1 Not described HAT 0%, PVT 6% [12] Switzerland R/C LT 0-18 UFH, ASA, FFP HAT 1.8%, PVT 0.9% Millis (1996) [19] USA R/C LDLT/RLT 0-3 Not described ePVT 4-33%; dPVT 4-51% Miyagi (2014) [88] Japan R/C LDLT All Protease inhibitor Not reported Nagra (2004) [48] UK R/C KT 0-17 UFH vs. No prophylaxis GT 8% vs. 11% Neto (2007) [89] Brazil P/C LDLT < 10 kg 0-18 Not described HAT 3.1%, PVT 5.4% Neto (2012) [10] Brazil P/C LDLT 0-18 Not described HAT 4.3%, ePVT 2.6%, dPVT 5.8% Neto (2014) [90] Brazil P/C LDLT 0-18 UFH/VKA in high risk, dipyridamole PVT 7%…”
Section: Thromboprophylaxismentioning
confidence: 99%
“…Jurim (1995) [79] USA R/C LT/RLT 0-10 Not described HAT 29% (LT) vs. 0% (RLT) Kamel (2006) [80] Ireland R/C KT 0-18 None GT 5% Kanmaz (2014) [13] Turkey R/C LT 0-18 ASA HAT 3.9%, PVT 6.8% Karatzas (1997) [81] USA R/C LT All Not described HAT 11.4% Khan (2014) [82] Saudi Arabia R/C KT 0- [86] Italy R/C LT, < 6 kg 0-1 Not described HAT 0%, PVT 6% [12] Switzerland R/C LT 0-18 UFH, ASA, FFP HAT 1.8%, PVT 0.9% Millis (1996) [19] USA R/C LDLT/RLT 0-3 Not described ePVT 4-33%; dPVT 4-51% Miyagi (2014) [88] Japan R/C LDLT All Protease inhibitor Not reported Nagra (2004) [48] UK R/C KT 0-17 UFH vs. No prophylaxis GT 8% vs. 11% Neto (2007) [89] Brazil P/C LDLT < 10 kg 0-18 Not described HAT 3.1%, PVT 5.4% Neto (2012) [10] Brazil P/C LDLT 0-18 Not described HAT 4.3%, ePVT 2.6%, dPVT 5.8% Neto (2014) [90] Brazil P/C LDLT 0-18 UFH/VKA in high risk, dipyridamole PVT 7%…”
Section: Thromboprophylaxismentioning
confidence: 99%